Mepacrine
| Clinical data | |
|---|---|
| Trade names | Atabrine, Atebrin | 
| AHFS/Drugs.com | Micromedex Detailed Consumer Information | 
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 80–90% | 
| Elimination half-life | 5–14 days | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.001.371 | 
| Chemical and physical data | |
| Formula | C23H30ClN3O | 
| Molar mass | 399.96 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Mepacrine, also called quinacrine or by the trade names Atabrine or Atebrin, is a medication with several uses. It is related to chloroquine and mefloquine. Although available from compounding pharmacies, as of August 2020 approved formulations are not available in the United States.